Strategies to examine new compounds for intraperitoneal use in ovarian cancer. (1st February 2008)

• Record Type: Journal Article
• Authors: Markman, M.
• Is Part Of: International journal of gynecological cancer. Volume 18(2008)Supplement 1
• Page Start: 33
• Page End: 35
• Publication Date: 2008-02-01
• Subjects: chemotherapy -- cisplatin -- intraperitoneal chemotherapy -- ovarian cancer; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1111/j.1525-1438.2007.01102.x
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : The results of three large well-designed randomized trials demonstrating the favorable impact of primary cisplatin-based chemotherapy on survival in small-volume residual advanced ovarian cancer has stimulated considerable interest in exploration of this route of drug delivery for other antineoplastic agents. A number of relevant properties of both the drugs and the peritoneal cavity need to be considered in preclinical evaluation such that future clinical development will focus on strategies that have a realistic potential for being safe and effective when they enter the clinical arena